The Impact of Hispanic Ethnicity and the Titration Effect of LY2189265, a Glucagon-Like Peptide 1 Analog, on Metabolic Outcome Measures in Patients with Uncontrolled Type 2 Diabetes Mellitus (T2DM): An EGO Study Analysis.

被引：0
|
作者：
Bastyr, E. J., III [1 ,2 ]
Cheng, C. L. [1 ]
Noriega, J. E. [1 ,2 ]
Thompson, A. B. [1 ]
Threlkeld, R. J. [1 ]
Shu, J. [3 ]
Glass, L. C. [1 ]
机构：
[1] Lilly Res Labs, Indianapolis, IN USA
[2] Indiana Univ, Sch Med, Indianapolis, IN USA
[3] i3 Statprobe, Ann Arbor, MI USA
来源：
ENDOCRINE REVIEWS | 2010年 / 31卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Evaluating the Impact of Glucagon-Like Peptide-1 Receptor Agonists on Metabolic Changes in Patients With Type 2 Diabetes on High-Dose Insulin
    Rentsch, Tiffany
    Awad, Magdi
    Moorman, John M.
    Gothard, Michael David
    AMERICAN JOURNAL OF THERAPEUTICS, 2022, 29 (06) : E632 - E636
  • [42] Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Outcomes in Black Patients with Type 2 Diabetes Mellitus: A Meta-Analysis of Recent Cardiovascular Outcome Trials
    Koutroumpakis, Efstratios
    Taegtmeyer, Heinrich
    Aguilar, David
    CIRCULATION, 2019, 139
  • [43] CARDIOVASCULAR BENEFIT OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS IN FEMALE PATIENTS WITH TYPE 2 DIABETES MELLITUS: A META-ANALYSIS OF RECENT CARDIOVASCULAR OUTCOME TRIALS
    Aguilar, David
    Koutroumpakis, Efstratios
    Taegtmeyer, Heinrich
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (09) : 239 - 239
  • [44] Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on plasma omentin-1 levels in patients with type 2 diabetes mellitus
    Yan, Pijun
    Li, Ling
    Yang, Mengliu
    Liu, Dongfang
    Liu, Hua
    Boden, Guenther
    Yang, Gangyi
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2011, 92 (03) : 368 - 374
  • [45] Favorable liver and skeletal muscle changes in patients with MASLD and T2DM receiving glucagon-like peptide-1 receptor agonist: A prospective cohort study
    Kakegawa, Tatsuya
    Sugimoto, Katsutoshi
    Saito, Kazuhiro
    Yunaiyama, Daisuke
    Araki, Yoichi
    Wada, Takuya
    Takahashi, Hiroshi
    Yoshimasu, Yu
    Takeuchi, Hirohito
    Itoi, Takao
    MEDICINE, 2024, 103 (23)
  • [46] Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus: A systematic review and meta-analysis
    Pulipati, Vishnu Priya
    Ravi, Venkatesh
    Pulipati, Priyanjali
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2020, 27 (18) : 1922 - 1930
  • [47] Secretion of Glucagon-Like Peptide-1 in Patients With Type 2 Diabetes Mellitus-Systematic Review and Meta-Analysis of Clinical Studies
    Calanna, Salvatore
    Gluud, Lise L.
    Holst, Jens J.
    Vilsboll, Tina
    Knop, Filip K.
    DIABETES, 2012, 61 : A482 - A482
  • [48] Impact of anti-diabetic therapy based on glucagon-like peptide-1 receptor agonists on the cardiovascular risk of patients with type 2 diabetes mellitus
    Camafort-Babkowski, Miguel
    MEDICINA CLINICA, 2013, 141 (04): : 167 - 174
  • [49] Effect of glucagon-like peptide 1 receptor agonists on the renal protection in patients with type 2 diabetes: A systematic review and meta-analysis
    Li, Xiang
    Song, Yujie
    Guo, Tao
    Xiao, Guiying
    Li, Qiumei
    DIABETES & METABOLISM, 2022, 48 (05)
  • [50] Glucagon-Like Peptide 1 Receptor Agonist or Rapid-Acting Insulin as Add-on to Basal Insulin Therapy in T2DM Patients: A Meta-analysis
    Kuritzky, Louis
    Lin, Jay
    Wysham, Carol H.
    DIABETES, 2015, 64 : A284 - A285
12345